SynFlowNet: Synthesizable Molecule Design

• SynFlowNet is a generative flow network that constructs molecules through iterative application of reaction templates and purchasable reactants, ensuring synthetic feasibility.
• It frames molecular synthesis as a Markov Decision Process with a structured action space including reactant addition, reaction execution, and termination.
• It employs trajectory balance and backward-policy regularization to optimize for diverse, high-reward molecules with explicit synthetic routes and interpretable chemical insights.

SynFlowNet is a generative flow network (GFlowNet) model for molecular design that constructs molecules by iteratively applying chemical reactions to purchasable reactants, explicitly incorporating synthetic feasibility into the generative process. By defining an action space structured around documented reaction templates and commercially available building blocks, SynFlowNet produces not only chemically valid but also readily synthesizable molecules and their synthetic pathways. The architecture and training objectives target coverage of diverse, high-reward regions of molecular space, addressing major obstacles in computer-aided drug design—specifically, the tendency of traditional generative models to output synthetically inaccessible compounds (Cretu et al., 2024).

1. Markov Decision Process Formulation

SynFlowNet formulates molecule synthesis as a finite-horizon Markov Decision Process (MDP), in which:

• State space $S$: Each state $s \in S$ represents a partial molecular graph constructed from atoms (with one-hot element type, formal charge, aromaticity) and bonds (type, bi-molecular reaction attachment flags). Additionally, a virtual node encodes global context. States are maintained as both molecular graphs and sequences of reaction steps (Cretu et al., 2024).
• Action space $\mathcal{A}_F$ (forward, 5 types):

1. AddFirstReactant: Choose an Enamine building block (BB) as the initial reactant from a curated set ($>220\,\!000$ unique purchasable fragments).
2. ReactUni: Select a unimolecular reaction template (SMARTS-based) and apply to the current intermediate.
3. ReactBi: Select a bimolecular reaction template.
4. AddReactant: Choose an additional BB compatible with the chosen bi-molecular template.
5. Stop: Conclude the sequence and output the final molecule.

• Transition dynamics: Forward transitions apply reaction templates (and BBs, if bi-molecular). Masking enforces synthetic feasibility at each step by only admitting templates and BBs that match the current state. All valid trajectories correspond to realizable multi-step syntheses from available materials.
• Architecture: A graph transformer processes molecular graphs to hidden states. Separate multi-layer perceptron (MLP) heads predict logits for each forward/backward action. For AddReactant, the model computes normalized dot products between the hidden state and fixed Morgan fingerprints of all BBs to scale to large BB libraries efficiently (Cretu et al., 2024, S et al., 24 Nov 2025).

2. Training Objectives and Loss Functions

The GFlowNet framework requires learning forward and backward policies while enforcing global flow consistency for sampling terminal molecules with probability proportional to a reward function.

• Trajectory Balance Objective:

$$\mathcal{L}_{\rm TB}(\tau) = \left(\log \frac{Z_\theta \prod_{t=0}^{T-1} P_F(s_{t+1} \mid s_t; \theta)}{R(x) \prod_{t=1}^T P_B(s_{t-1}\mid s_t; \theta)} \right)^2$$

where $R(x)$ is a scalar reward (e.g., predicted biological activity, QED, synthetic accessibility) and $Z_\theta$ is a learnable partition function. This loss guarantees that the marginal distribution over terminal molecules induced by the forward policy $P_F$ matches the reward-weighted distribution (Cretu et al., 2024).

• Auxiliary Backward-Policy Loss: Additional objectives are introduced to directly train the backward policy $P_B$, crucial for avoiding invalid backward transitions.
  • Maximum Likelihood: Encourages $P_B$ to recover parent states sampled in actual forward trajectories.
  • REINFORCE with entropy regularization: Maximizes the chance of returning to the initial state $s \in S$0 and penalizes dead-ends, regularizing for exploration (Cretu et al., 2024).

No auxiliary diversity loss is required, as the flow-matching training objective inherently promotes coverage of multiple diverse high-reward modes in the molcular space (Cretu et al., 2024).

3. Backward Policy and Synthetic Constraints

Backward transitions in SynFlowNet serve to reconstruct valid parental states by undoing reactions.

• Definition and Challenges: The backward policy $s \in S$1 distributes probability mass over all synthetically plausible parent states. For some molecules, naive inversion of templates may yield "reactants" that cannot themselves be traced back to purchasable BBs—these correspond to MDP dead ends.
• Training Strategies:
  • Fixed Uniform: Assigns probability equally to all candidates, but wastes flow on dead ends and performs suboptimally.
  • Free Parameterization (Trajectory Balance Only): Trained exclusively with the main loss, may still allocate flow to invalid transitions.
  • Maximum Likelihood: Trained to favor only parents occurring in recent valid forward trajectories.
  • REINFORCE: Explicitly maximizes recovery to $s \in S$2; empirically, this approach "yielded the highest fraction of solved routes (100% on train, 44% on held-out)" and maximized the number of high-reward, synthetically feasible molecules discovered [(Cretu et al., 2024), Table 3].

A plausible implication is that backward-policy regularization addresses the unique challenge of reaction-based MDPs—excluding spurious "retrosynthetic" paths not accessible from actual building blocks.

4. Quantitative Performance and Baseline Comparisons

SynFlowNet is quantitatively benchmarked using several metrics and compared to prior generative strategies.

• Synthetic Accessibility (SA) Score: SAScore(x) $s \in S$3, where lower values indicate greater synthetic feasibility. SynFlowNet achieves SA $s \in S$4 for high-reward molecules (vs. FragGFN's $s \in S$5) [(Cretu et al., 2024), Table 4].
• Retrosynthesis Success (AiZynthFinder): Fraction of generated molecules for which an independent tool identifies a valid multi-step synthetic route. SynFlowNet attains 65% retrosynthesis success for high-reward molecules, versus 0% for fragment-based GFlowNet, confirming that designs are not only theoretically feasible but recognized by established retrosynthetic planning software (Cretu et al., 2024).
• Diversity (Tanimoto Fingerprints): Mean pairwise Tanimoto distance (2048-bit Morgan fingerprints) demonstrates that SynFlowNet covers >10x more scaffolds than entropy-regularized Q-learning and achieves higher novelty with respect to ChEMBL than REINVENT (similarity ≈0.43 vs ≈0.64) (Cretu et al., 2024).

Model	SA Score (lower better)	Retrosynthesis %	Max Novelty (vs ChEMBL)
SynFlowNet	2.9	65%	≈0.43
FragGFN	6.3	0%	—
REINVENT	—	—	≈0.64

These results demonstrate that integrating synthesis constraints at generation time yields a distinct advantage over fragment- or SMILES-based workflows in balancing novelty, synthetic tractability, and property optimization.

5. Interpretability: Mechanisms and Chemical Reasoning

SynFlowNet has been further analyzed for interpretability through gradient-based saliency, counterfactual mutagenesis, autoencoder-based latent factor analysis, and motif probing (S et al., 24 Nov 2025).

• Gradient-Based Saliency: Integrated gradients applied to the Stop action localize atomic contributions to reward, producing interpretable atom- and motif-level saliency maps. High-scoring regions often correspond to polar substituents, heterocycles, and aromatic rings—aligning with medicinal chemistry heuristics.
• Counterfactual Editing: Saliency-derived motifs are systematically mutated using chemistry-guided transformations (e.g., amide → ester, methyl → fluorine), and the impact on QED is recorded. This enables prescriptive suggestions, such as "convert amide to ester for increased drug-likeness" when a positive change in QED (e.g., $s \in S$6QED = $s \in S$7) is observed within the same route context.
• Sparse Autoencoder Analysis: Latent factors extracted from pooled graph embeddings are markedly axis-aligned. For example:
  • "Factor 11" correlates with molecular size ($s \in S$8)
  • "Factor 86" correlates negatively with polarity ($s \in S$9)
  • "Factor 118" correlates positively with polarity ($\mathcal{A}_F$0)
  • Linear projections from these factors explain variance in size and polarity more accurately (R²=0.71, 0.92) than direct QED scores.
• Motif Probes: Probes trained to recognize SMARTS-defined functional groups from the model's internal representations achieve AUROC ≈ 1.00 for halogens and aromatic rings, ≥0.92 for amides, esters, etc., confirming the network’s encoding aligns with standard medicinal chemistry motifs.

These interpretability modules reveal the chemical logic encoded by SynFlowNet’s policies, enabling mechanistic rationalization of design choices and actionable guidance for structure optimization (S et al., 24 Nov 2025).

6. Applications and Representative Pathways

SynFlowNet provides both optimized molecular candidates and explicit multi-step synthetic routes.

• Synthetic Route Generation: For example, a three-step synthesis to 4-fluoro-phenylacetamide is proposed—via fluorobenzene, acylation, and amidation—paralleling realistic laboratory protocols (Cretu et al., 2024).
• Medicinal Chemistry Utility: Combined interpretability techniques allow fine-grained interventions. In one case, starting from 2-chloropyridine, saliency identifies the chloride as a key decision point; motif probing confirms halogen representation; counterfactuals recommend bromide exchange; latent factors suggest polar group addition for optimal reward—mirroring real-world lead optimization strategies (S et al., 24 Nov 2025).

A plausible implication is that such mechanistic transparency bridges the gap between in silico design and human chemist intuition, supporting both hypothesis-driven molecule engineering and automated compound library generation under real-world synthesis constraints.

---

References:

• (Cretu et al., 2024) SynFlowNet: Design of Diverse and Novel Molecules with Synthesis Constraints
• (S et al., 24 Nov 2025) Interpreting GFlowNets for Drug Discovery: Extracting Actionable Insights for Medicinal Chemistry